Global Monovaccine(Epstein-Barr Virus) Market potential, by Application (Mononucleosis,Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiplesclerosis, and Nasopharyngeal Carcinoma) and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) is estimated to be US$2.0 Bn.
Frequent research and developmentactivities and funding by various organizations is expected to lead to thedevelopment of monovaccine in future. Currently, there is no licensed vaccinefor EBV. However, various universities and organizations are taking efforts todevelop novel vaccines and fulfill unmet needs. For instance, in March 2017,Cancer Research U.K. completed its phase 1b clinical trial of (ModifiedVaccinia Ankara) MVA-EBNA1/LMP2 vaccine. It is being treated on nasopharyngealcancer patients with positive Epstein-Barr virus infection. In 2017,researchers from the University of Kansas School of Engineering and School ofPharmacy analyzed the genetics of human immune responses to develop basis of aneffective vaccine or drug therapy against Epstein-Barr virus or EBV, thepathogen that causes infectious mononucleosis and infects around 90% of adultsworldwide. In January 2019, researchers and scientists from the German CancerResearch Center developed a new strategy for creating a vaccine that targetsdifferent EBV virus life phases and has the potential to provide effectiveprotection against EBV infection. Hence, frequent monovaccine developmentefforts by various universities is expected to result in development of novelvaccines and fulfill unmet needs in the near future.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2002
Browse 10 Market Data Tables and10 Figures spread through 84 Pages and in-depth TOC on Global Monovaccine(Epstein - Barr virus) Market by Application (Mononucleosis, Endemic Burkitt’slymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, andNasopharyngeal Carcinoma) and Region (North America, Latin America, Europe,Asia Pacific, the Middle East, and Africa)
Various government organizationsfrom different regions are taking efforts for the development of novelmonovaccines (Epstein - Barr virus) and gaining approval. For instance, in2019, researchers from National Institutes of Health’s (NIH) National Instituteof Allergy and Infectious Diseases (NIAID) determined how various antibodiesinduced by Epstein-Barr virus (EBV) block infection of cells grown in thelaboratory. Researchers used this information for development of novel vaccinecandidates in animals, elicited potent anti-EBV antibody responses that blockedinfection of cell types involved in EBV-associated cancers.
Key Takeaways of the GlobalMonovaccine (Epstein-Barr virus) Market:
Currently, there is no approvedmonovaccines in any region. However, various universities are involved inrobust research and development activities for monovaccines.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/mono-vaccines-epstein-barr-virus-market-2002
High prevalence of Epstein-Barrvirus infections is expected to rise the demand for its vaccine in future. Forinstance, according to the study published by Cincinnati Children's HospitalMedical Center, in 2018, Epstein-Barr virus is a very common virus in the U.S.and other developed regions.
Emerging economies are expectedto be more potential regions for vaccine, as chances of infection with EBV arehigh. For instance, according to the study published by Cincinnati Children'sHospital Medical Center, in 2018, around 90% of the population becomes infectedwith EBV virus by age 20. In emerging economies, 90% of people are infected byage of 2 years.
Furthermore, Asia Pacific isexpected to be a potential market for nasopharyngeal cancer vaccine as theprevalence of nasopharyngeal cancer is high in Asia Pacific. For instance,according to American Cancer Society, nasopharyngeal cancer is more common inseveral regions including South Asia, Middle East, and North Africa. In someparts of China, there are as many as 21 cases per 100,000 people. The diseaseis also more common among Inuit of Alaska and Canada.
Universities and organizationsinvolved in development of monovaccine (Epstein-Barr virus) include CancerResearch U.K., National Institutes of Health, Chinese University of Hong Kong,Genome Biosciences, Inc., Dana-Farber Cancer Institute, German Cancer ResearchInstitute, and University of Minnesota.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2002
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
